骨质疏松症治疗药物研究进展

被引：1

作者：

吴晞

机构：

[1] 复旦大学附属华山医院内分泌科

来源：

上海医药 | 2013年 / 34卷 / 09期

关键词：

骨质疏松症; 硬化蛋白抗体; 组织蛋白酶K抑制剂; 核因子κB受体活化因子配体拮抗剂;

D O I：

暂无

中图分类号：

R580 [];

学科分类号：

摘要：

骨质疏松症治疗药物在最近10年内有比较大的发展。本文简要介绍其中3类药物的作用机制和临床研究进展。

引用

收藏

页码：10 / 12

页数：3

相关论文

共 8 条

[1]

Odanacatib in the Treatment of Postmenopausal Women With Low Bone Mineral Density: Five Years of Continued Therapy in a Phase 2 Study [J].

Langdahl, Bente ;

Binkley, Neil ;

Bone, Henry ;

Gilchrist, Nigel ;

Resch, Heinrich ;

Portales, Jose Rodriguez ;

Denker, Andrew ;

Lombardi, Antonio ;

De Tilleghem, Celine Le Bailly ;

DaSilva, Carolyn ;

Rosenberg, Elizabeth ;

Leung, Albert .

JOURNAL OF BONE AND MINERAL RESEARCH, 2012, 27 (11) :2251-2258

[2]

Bisphosphonates in the Treatment of Osteoporosis [J].

Diab, Dima L. ;

Watts, Nelson B. .

ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2012, 41 (03) :487-+

[3]

Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX [J].

McCloskey, Eugene V. ;

Johansson, Helena ;

Oden, Anders ;

Austin, Matt ;

Siris, Ethel ;

Wang, Andrea ;

Lewiecki, E. Michael ;

Lorenc, Roman ;

Libanati, Cesar ;

Kanis, John A. .

JOURNAL OF BONE AND MINERAL RESEARCH, 2012, 27 (07) :1480-1486

[4]

Impact of clinical fractures on health-related quality of life is dependent on time of assessment since fracture: results from the FREEDOM trial [J].

Silverman, S. ;

Viswanathan, H. N. ;

Yang, Y-C. ;

Wang, A. ;

Boonen, S. ;

Ragi-Eis, S. ;

Fardellone, P. ;

Gilchrist, N. ;

Lips, P. ;

Nevitt, M. ;

Palacios Gil-Antunano, S. ;

Pavelka, K. ;

Revicki, D. ;

Simon, J. ;

Macarios, D. ;

Siris, E. S. .

OSTEOPOROSIS INTERNATIONAL, 2012, 23 (04) :1361-1369

[5]

Inhibition of Cathepsin K for Treatment of Osteoporosis [J].

Boonen, Steven ;

Rosenberg, Elizabeth ;

Claessens, Frank ;

Vanderschueren, Dirk ;

Papapoulos, Socrates .

CURRENT OSTEOPOROSIS REPORTS, 2012, 10 (01) :73-79

[6]

Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension [J].

Papapoulos, Socrates ;

Chapurlat, Roland ;

Libanati, Cesar ;

Brandi, Maria Luisa ;

Brown, Jacques P. ;

Czerwinski, Edward ;

Krieg, Marc-Antoine ;

Man, Zulema ;

Mellstrom, Dan ;

Radominski, Sebastiao C. ;

Reginster, Jean-Yves ;

Resch, Heinrich ;

Roman Ivorra, Jose A. ;

Roux, Christian ;

Vittinghoff, Eric ;

Austin, Matthew ;

Daizadeh, Nadia ;

Bradley, Michelle N. ;

Grauer, Andreas ;

Cummings, Steven R. ;

Bone, Henry G. .

JOURNAL OF BONE AND MINERAL RESEARCH, 2012, 27 (03) :694-701

[7]

Adverse drug reactions to osteoporosis treatments.[J].Rizzoli;Reginster.Expert Review of Clinical Pharmacology.2011, 5

[8]

Interim report and recommendations of the World Health Organization task-force for osteoporosis [J].

Genant, HK ;

Cooper, C ;

Poor, G ;

Reid, I ;

Ehrlich, G ;

Kanis, J ;

Nordin, BEC ;

Barrett-Connor, E ;

Black, D ;

Bonjour, JP ;

Dawson-Hughes, B ;

Delmas, PD ;

Dequeker, J ;

Eis, SR ;

Gennari, C ;

Johnell, O ;

Johnston, CC ;

Lau, EMC ;

Liberman, UA ;

Lindsay, R ;

Martin, TJ ;

Masri, B ;

Mautalen, CA ;

Meunier, PJ ;

Miller, PD ;

Mithal, A ;

Morii, H ;

Papapoulos, S ;

Woolf, A ;

Yu, W ;

Khaltaev, N .

OSTEOPOROSIS INTERNATIONAL, 1999, 10 (04) :259-264